Literature DB >> 6061746

Cortisol metabolism in cirrhosis.

B Zumoff, H L Bradlow, T F Gallagher, L Hellman.   

Abstract

The production and peripheral metabolism of cortisol have been studied in 10 cirrhotics and 11 controls after i.v. tracers of cortisol-(14)C. The findings were as follows: (a) Total urinary excretion of radioactivity was normal (81% of the dose) but a decreased fraction was present as glucosiduronates: 18-47% of the dose (average 34%) compared to a normal average of 54%. (b) There was a distinctively abnormal pattern of cortisol metabolites, not previously observed in other illnesses: tetrahydrocortisone was decreased to 14% of the enzyme hydrolysate (normal 26%); cortolones were increased to 34% (normal 19%), owing entirely to an increase in cortolone (20alpha) formation, since beta-cortolone (20beta) was not significantly increased; Reichstein's substances U and epi-U were increased, averaging 2.6% for the former and 4.7% for the latter; tetrahydrocortisol, allotetrahydrocortisol and cortols were normal. This pattern was independent of the degree of decreased glucosiduronate formation and also independent of the presence or absence of a portacaval shunt. (c) Cortisol production, determined by isotope dilution, was normal in each of six cirrhotic patients. From these data, taken in conjunction with our previously reported findings concerning the influence of norethandrolone on cortisol metabolism, the following conclusions were drawn: (a) Cirrhotic patients have decreased A-ring reduction of cortisone to tetrahydrocortisone and correspondingly increased 20-ketone reduction of cortisone to Reichstein's substances U and epi-U and then to the cortolones. (b) Intrahepatic cholestasis, a regular pathophysiological feature of cirrhosis, may be responsible for the observed abnormal cortisol metabolite pattern in this disease. (c) The slowed metabolic turnover rate of cortisol in cirrhosis may be due to decreased transport and/or binding of cortisol to its intracellular metabolic sites rather than to abnormalities of any specific metabolizing enzymes.

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 6061746      PMCID: PMC292924          DOI: 10.1172/JCI105664

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  10 in total

1.  Metabolism of Reichstein's substance E in man.

Authors:  H L BRADLOW; D K FUKUSHIMA; B ZUMOFF; L HELLMAN; T F GALLAGHER
Journal:  J Clin Endocrinol Metab       Date:  1962-07       Impact factor: 5.958

2.  Studies with an adrenal inhibitor in adrenal carcinoma.

Authors:  D K FUKUSHIMA; T F GALLAGHER; W GREENBERG; O H PEARSON
Journal:  J Clin Endocrinol Metab       Date:  1960-09       Impact factor: 5.958

3.  The validity of the calculation of secretion rates from the specific activity of a urinary metabolite.

Authors:  K R LAUMAS; J F TAIT; S A TAIT
Journal:  Acta Endocrinol (Copenh)       Date:  1961-02

4.  Metabolic transformation of hydrocortisone-4-C14 in normal men.

Authors:  D K FUKUSHIMA; H L BRADLOW; L HELLMAN; B ZUMOFF; T F GALLAGHER
Journal:  J Biol Chem       Date:  1960-08       Impact factor: 5.157

5.  Adrenocortical steroid metabolism and adrenal cortical function in liver disease.

Authors:  R E PETERSON
Journal:  J Clin Invest       Date:  1960-02       Impact factor: 14.808

6.  The physiological disposition and metabolic fate of hydrocortisone in man.

Authors:  R E PETERSON; J B WYNGAARDEN; S L GUERRA; B B BRODIE; J J BUNIM
Journal:  J Clin Invest       Date:  1955-12       Impact factor: 14.808

7.  [Role of the liver in the metabolism of corticoids].

Authors:  A VERMEULEN; L DEMEULENAERE
Journal:  Rev Fr Etud Clin Biol       Date:  1956-04

8.  17-Hydroxycorticosteroid metabolism in liver disease.

Authors:  H BROWN; D G WILLARDSON; L T SAMUELS; F H TYLER
Journal:  J Clin Invest       Date:  1954-11       Impact factor: 14.808

9.  Determination in plasma of free 17-hydroxy and 17-desoxy corticosteroids and their glucuronic-acid conjugates.

Authors:  T E WEICHSELBAUM; H W MARGRAF
Journal:  J Clin Endocrinol Metab       Date:  1955-08       Impact factor: 5.958

10.  The urinary excretion of tetrahydrocortisol, 3 alpha-allotetrahydrocortisol and tetrahydrocortisone in young and elderly men and women.

Authors:  L P ROMANOFF; R M RODRIGUEZ; J M SEELYE; C PARENT; G PINCUS
Journal:  J Clin Endocrinol Metab       Date:  1958-11       Impact factor: 5.958

  10 in total
  8 in total

1.  Hepatic porphyrins and urinary porphyrins and porphyrin precursors in liver cirrhosis.

Authors:  M Doss; D Look; H Henning; P Nawrocki; A Schmidt; W Dölle; G Korb; C J Lüders; G Strohmeyer
Journal:  Klin Wochenschr       Date:  1972-11-15

2.  [Production and metabolism of corticosteroids and androgens in liver cirrhosis].

Authors:  H J Karl; M Wiedemann; L Raith
Journal:  Klin Wochenschr       Date:  1971-03-15

3.  Cortisol and dexamethasone elimination during treatment with cimetidine.

Authors:  N R Peden; I Rewhorn; M C Champion; R Mussani; T C Ooi
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

4.  Estradiol metabolism in cirrhosis.

Authors:  B Zumoff; J Fishman; T F Gallagher; L Hellman
Journal:  J Clin Invest       Date:  1968-01       Impact factor: 14.808

5.  Estrogen and androgen dynamics in liver disease.

Authors:  C Longcope; J H Pratt; S Schneider; E Fineberg
Journal:  J Endocrinol Invest       Date:  1984-12       Impact factor: 4.256

6.  Bile acids and their amidates inhibit 11 beta-hydroxysteroid dehydrogenase obtained from rat kidney.

Authors:  F H Perschel; H Bühler; K Hierholzer
Journal:  Pflugers Arch       Date:  1991-07       Impact factor: 3.657

7.  Decreased maximal cortisol secretion rate in patients with cirrhosis: Relation to disease severity.

Authors:  Christina M Lovato; Thierry Thévenot; Sophie Borot; Vincent Di Martino; Clifford R Qualls; Frank K Urban; Richard I Dorin
Journal:  JHEP Rep       Date:  2021-03-19

8.  Plasma fetal bile acids 7α-hydroxy-3-oxochol-4-en-24-oic acid and 3-oxachola-4,6-dien-24-oic acid indicate severity of liver cirrhosis.

Authors:  Tudor Mocan; Dong Wook Kang; Billy J Molloy; Hyeonho Jeon; Zeno A Spârchez; Diren Beyoğlu; Jeffrey R Idle
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.